Efficacy of daratumumab in refractory primary Sjögren disease

Detalles Bibliográficos
Autores principales: Nocturne, Gaetane, Marmontel, Oriane, di Filippo, Mathilde, Chretien, Pascale, Krzysiek, Roman, Lifermann, Francois, Rahal, Nawal, Belkhir, Rakiba, Moulin, Philippe, Mariette, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Sjögren Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510860/
https://www.ncbi.nlm.nih.gov/pubmed/37730313
http://dx.doi.org/10.1136/rmdopen-2023-003464
_version_ 1785108032968982528
author Nocturne, Gaetane
Marmontel, Oriane
di Filippo, Mathilde
Chretien, Pascale
Krzysiek, Roman
Lifermann, Francois
Rahal, Nawal
Belkhir, Rakiba
Moulin, Philippe
Mariette, Xavier
author_facet Nocturne, Gaetane
Marmontel, Oriane
di Filippo, Mathilde
Chretien, Pascale
Krzysiek, Roman
Lifermann, Francois
Rahal, Nawal
Belkhir, Rakiba
Moulin, Philippe
Mariette, Xavier
author_sort Nocturne, Gaetane
collection PubMed
description
format Online
Article
Text
id pubmed-10510860
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105108602023-09-21 Efficacy of daratumumab in refractory primary Sjögren disease Nocturne, Gaetane Marmontel, Oriane di Filippo, Mathilde Chretien, Pascale Krzysiek, Roman Lifermann, Francois Rahal, Nawal Belkhir, Rakiba Moulin, Philippe Mariette, Xavier RMD Open Sjögren Syndrome BMJ Publishing Group 2023-09-19 /pmc/articles/PMC10510860/ /pubmed/37730313 http://dx.doi.org/10.1136/rmdopen-2023-003464 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Sjögren Syndrome
Nocturne, Gaetane
Marmontel, Oriane
di Filippo, Mathilde
Chretien, Pascale
Krzysiek, Roman
Lifermann, Francois
Rahal, Nawal
Belkhir, Rakiba
Moulin, Philippe
Mariette, Xavier
Efficacy of daratumumab in refractory primary Sjögren disease
title Efficacy of daratumumab in refractory primary Sjögren disease
title_full Efficacy of daratumumab in refractory primary Sjögren disease
title_fullStr Efficacy of daratumumab in refractory primary Sjögren disease
title_full_unstemmed Efficacy of daratumumab in refractory primary Sjögren disease
title_short Efficacy of daratumumab in refractory primary Sjögren disease
title_sort efficacy of daratumumab in refractory primary sjögren disease
topic Sjögren Syndrome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510860/
https://www.ncbi.nlm.nih.gov/pubmed/37730313
http://dx.doi.org/10.1136/rmdopen-2023-003464
work_keys_str_mv AT nocturnegaetane efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT marmonteloriane efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT difilippomathilde efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT chretienpascale efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT krzysiekroman efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT lifermannfrancois efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT rahalnawal efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT belkhirrakiba efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT moulinphilippe efficacyofdaratumumabinrefractoryprimarysjogrendisease
AT mariettexavier efficacyofdaratumumabinrefractoryprimarysjogrendisease

Ejemplares similares